ReviewCancer cell international2021
Tumor-infiltrating B cells as a favorable prognostic biomarker in breast cancer: a systematic review and meta-analysis.
Review in Cancer cell international, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 34 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
34 citing papers in PubMed.
- B Cells and Tumor Immunometabolism: Emerging Insights into Immune Regulation and Therapeutic Resistance.Antibodies (Basel, Switzerland) · 2026Review
- The contribution of rare germline variants to the immune landscape of breast cancer.Genome medicine · 2026Article
- Article
- Tumor ecosystem subtyping of breast cancer based on somatic mutations and network propagation reveals distinct prognostic and genomic landscapes.Frontiers in genetics · 2026Article
- B-cells in breast cancer: current insights and challenges.Frontiers in oncology · 2026Review
- Spatial characterization of tertiary lymphoid structures as predictive biomarkers for immune checkpoint blockade in head and neck squamous cell carcinoma.Oncoimmunology · 2025Article
- Article
- Immunogenomic diversity of triple-negative breast cancers in obese and non-obese black and white women.NPJ breast cancer · 2025Article
- Profiling antigen-binding affinity of B cell repertoires in tumors by deep learning predicts immune-checkpoint inhibitor treatment outcomes.Nature cancer · 2025Article
- The Role of Tumor Microenvironment in Triple-Negative Breast Cancer and Its Therapeutic Targeting.Cells · 2025Review
- Breast Cancer and Tumor Microenvironment: The Crucial Role of Immune Cells.Current oncology (Toronto, Ont.) · 2025Review
- B cells enhance IL-1 beta driven invasiveness in triple negative breast cancer.Scientific reports · 2025Article
- Identification of primary mediastinal B-cell lymphomas with higher clonal dominance and poorer outcome using 5'RACE.Blood advances · 2025Article
- Advances in tumor-infiltrating B lymphocytes.Central-European journal of immunology · 2025Review
- A Comprehensive Methodology for Immortalizing Tumor-Infiltrating B Lymphocytes from Epithelial Cancers.Methods in molecular biology (Clifton, N.J.) · 2025Article
- Tumor microenvironment and immunotherapy for triple-negative breast cancer.Biomarker research · 2024Review
- B cells enhance IL-1 beta driven invasiveness in triple-negative breast cancer.Research square · 2024Article
- Enhancing AI Research for Breast Cancer: A Comprehensive Review of Tumor-Infiltrating Lymphocyte Datasets.Journal of imaging informatics in medicine · 2024Review
- B cell c-Maf signaling promotes tumor progression in animal models of pancreatic cancer and melanoma.Journal for immunotherapy of cancer · 2024Article
- Immune environment of high-TIL breast cancer: triple negative and hormone receptor positive HER2 negative.NPJ breast cancer · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
backgroundTumor-infiltrating B lymphocytes (TIL-Bs) is a heterogeneous population of lymphocytes. The prognostic value of TIL-Bs in patients with breast cancer remains controversial. Here we conducted this meta-analysis to clarify the association of TIL-Bs with outcomes of patients with breast cancer.
methodsWe searched PubMed, Embase, and Web of Science to identify relevant studies assessing the prognostic significance of TIL-Bs in patients with breast cancer. Fixed- or random-effects models were used to evaluate the pooled hazard ratios (HRs) for overall survival (OS), breast cancer-specific survival (BCSS), disease-free survival (DFS), and relapse-free survival (RFS) in breast cancer.
resultsA total of 8 studies including 2628 patients were included in our study. Pooled analyses revealed that high level of TIL-Bs was associated with longer OS (pooled HR = 0.42, 95% CI 0.24-0.60), BCSS (pooled HR = 0.66, 95% CI 0.47-0.85), and DFS/RFS (pooled HR = 0.41, 95% CI 0.27-0.55).
conclusionsThis meta-analysis suggests that TIL-Bs could be a promising prognostic marker for breast cancer. Novel therapeutic strategies for breast cancer treatment could be developed by enhancement of B cell-mediated antitumor immunity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.